Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Import Program Would Need Funds To Inspect All U.S. Pharmacies, Agency Maintains

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharmacy industry has told FDA all U.S. pharmacies will need to participate in a drug importation program to stay in business, so up to 55,000 pharmacies would have to be inspected, FDA's McGinnis says. "Draconian" penalties for non-complying drug manufacturers would ensure ample flow of drugs from Canada, he says.

You may also be interested in...



AARP Will Continue To Support Dorgan/Snowe Drug Import Bill In 2005

The organization maintains that the Dorgan bill addresses the safety concerns contained in the HHS Importation Task Force report. AARP’s legislative agenda includes supporting proposals to make Medicaid more efficient and expanding its Medicare Rx awareness campaign.

AARP Will Continue To Support Dorgan/Snowe Drug Import Bill In 2005

The organization maintains that the Dorgan bill addresses the safety concerns contained in the HHS Importation Task Force report. AARP’s legislative agenda includes supporting proposals to make Medicaid more efficient and expanding its Medicare Rx awareness campaign.

Rx Import Bills Do Not Have Adequate Funding For FDA, Agency Says

Senate bills "do not go far enough" in allowing FDA to assure safety and efficacy of imported drugs, FDA's Hubbard tells Judiciary Committee hearing. Senate Health Committee will mark up Sen. Gregg's import bill July 21.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel